BACKGROUND & AIMS:
Homozygous loss of function mutations in interleukin-10 (IL10) and interleukin-10 receptors (IL10R) cause severe infantile (very early onset) inflammatory bowel disease (IBD). Allogeneic hematopoietic stem cell transplantation (HSCT) was reported to induce sustained remission in 1 patient with IL-10R deficiency. We investigated heterogeneity among patients with very early onset IBD, its mechanisms, and the use of allogeneic HSCT to treat this disorder. METHODS: We analyzed 66 patients with early onset IBD (younger than 5 years of age) for mutations in the genes encoding IL-10, IL-10R1, and IL-10R2. IL-10R deficiency was confirmed by functional assays on patients' peripheral blood mononuclear cells (immunoblot and enzyme-linked immunosorbent assay analyses). We assessed the therapeutic effects of standardized allogeneic HSCT. RESULTS: Using a candidate gene sequencing approach, we identified 16 patients with IL-10 or IL-10R deficiency: 3 patients had mutations in IL-10, 5 had mutations in IL-10R1, and 8 had mutations in IL-10R2. Refractory colitis became manifest in all patients within the first 3 months of life and was associated with perianal disease (16 of 16 patients). Extraintestinal symptoms included folliculitis (11 of 16) and arthritis (4 of 16). Allogeneic HSCT was performed in 5 patients and induced sustained clinical remission with a median follow-up time of 2 years. In vitro experiments confirmed reconstitution of IL-10RϪmediated signaling in all patients who received the transplant. CONCLUSIONS: We identified loss of function mutations in IL-10 and IL-10R in patients with very early onset IBD. These findings indicate that infantile IBD patients with perianal disease should be screened for IL-10 and IL-10R deficiency and that allogeneic HSCT can induce remission in those with IL-10R deficiency.
Keywords: Children; Genetic Defect; Immunodeficiency; Intestinal Inflammation. I nflammatory bowel diseases (IBD) comprise a heterogeneous group of disorders, phenotypically classified as Crohn's disease, ulcerative colitis, and IBD unclassified. 1, 2 The etiology of these disorders remains largely obscure. Experimental studies and genetic evidence suggest that chronic intestinal inflammation is triggered by various environmental factors in genetically susceptible individuals. During the last decade, several genome-wide linkage and association studies have revealed a number of genetic polymorphisms associated with an increased susceptibility to Crohn's disease and ulcerative colitis. [3] [4] [5] [6] [7] [8] Genes that are implicated in the pathogenesis of IBD regulate various biological functions, such as immunomodulation, mucosal barrier integrity, and microbial homeostasis. 9 However, the functional significance of these genetic loci is controversial. Molecular analysis of rare Mendelian variants of IBD can also identify candidate genes implicated in IBD. 10, 11 We and others identified children with mutations in the interleukin-10 receptor (IL10R) 12 and inter -1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 leukin-10 (IL10) 13 genes. IL-10 represents a potent anti inflammatory and immunosuppressive cytokine that  mediates its pleiotropic effects on different immune cells  through the transmembrane heterotetrameric complex  composed of 2 IL-10R1 and IL-10R2 chains. 14 Although  IL-10R1 is specific to IL-10, IL-10R2 is a shared cytokine  receptor subunit mediating signals via IL-10, IL-22, IL-26 , and interferon-. 15 Because IL-10 acts predominantly on hematopoietic and immune cells, 14 transplantation of allogeneic hematopoietic stem cells might be considered as curative therapeutic approach. In fact, proof-of-concept could be demonstrated in one IL-10RϪdeficient patient. 12 Here, we analyzed a cohort of 66 patients with infantile (very early onset) IBD for mutations in the IL-10Ϫrelated genes and describe our experience of standardized allogeneic hematopoietic stem transplantation (HSCT) in 5 patients with IL-10R deficiency.
Materials and Methods

Patients and DNA Sanger Sequencing
We collected blood samples from 66 early-onset IBD patients with clinical onset at younger than 5 years of age (subgroup of the A1a entity according to the Paris classification 16 ), a severe course of disease, and different ethnic background. DNA Sanger sequencing of genes encoding for IL-10R1, IL-10R2, and IL-10 was performed upon parental written informed consent. The respective primer sequences are specified in Supplementary Table 1 . Clinical information on IL-10Ϫ and IL-10RϪdeficient patients was collected by their attending physicians. The study was approved by the Institutional Review Board at Hannover Medical School, Germany.
Western Blot Analysis and Enzyme-Linked Immunosorbent Assay
Whenever potentially disease-causing mutations were identified, we performed additional functional studies to validate IL-10R deficiency. Experimental details have previously been published. 12 In brief, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation and were stimulated with recombinant human IL-10 (25 ng/mL; PeproTech, Hamburg, Germany) for various time periods, followed by Western blot analysis of signal transducer and activator of transcription 3 phosphorylation at the residue tyrosine 705 (Tyr705, Cell Signaling, Danvers, MA), a crucial downstream event of IL-10 signal transduction. In addition, to exemplify defective IL-10Ϫmediated anti-inflammatory cytokine response, we harvested supernatants of lipopolysaccharide (LPS)-stimulated PBMCs (100 ng/mL; Sigma-Aldrich, Munich, Germany) and quantified tumor necrosis factorϪ␣ (TNF-␣) secretion upon costimulation with IL-10 (25 ng/mL) using a commercially available OptEIA ELISA kit according to manufacturer's instructions (BD Bioscience, San Jose, CA).
To assess the functional impact of the identified IL-10 mutation, we followed a previously published protocol. 13 In brief, we synthesized wild-type and mutant IL-10 by lentiviral-mediated overexpression of respective complementary DNAs in 293T cells, quantified the concentration of secreted IL-10 in the supernatants by enzyme-linked immunosorbent assay, and analyzed the suppression of TNF-␣ secretion in LPS/IL-10Ϫcostimulated healthy donor PBMCs.
Allogeneic HSCT
Allogeneic HSCT was considered in patients with confirmed diagnosis of IL-10R deficiency (mutational analysis, functional studies). To date, 5 patients with a severe and refractory course unresponsive to treatment with steroids, immunosuppressive agents, and surgery were treated by allogeneic HSCT after a standardized protocol. Patients had a conditioning regimen including alemtuzumab (1 mg/kg body weight), fludarabine (180 mg/m 2 body surface area), treosulfan (42 g/m 2 body surface area), and thiotepa (10 mg/kg body weight). Strict gut decolonization was performed with the use of colistin, amphotericin B (oral), ciprofloxacin, metronidazole, vancomycin (oral), fluconazole, and total parenteral nutrition during the peritransplantation period. Graft-vs-host disease (GVHD) prophylaxis included ciclosporin and mycophenolate mofetil. Infection prophylaxis was intensified with additional aciclovir and itraconazole substituting fluconazole on day 3 after HSCT. Tapering of the immunosuppressive medication was started at day ϩ100 in the absence of GVHD and included withdrawal of mycophenolate mofetil and dose reduction of ciclosporin by 10% every week. Hematopoietic chimerism was determined using restriction fragment length polymorphism. The reconstitution of IL-10RϪme-diated signal transduction in PBMCs from transplanted IL10RϪdeficient patients was validated by Western blot analysis and enzyme-linked immunosorbent assay as described.
Results
Genetic Analysis
We sequenced the genes encoding for IL-10R1, IL-10R2, and IL-10 in 66 patients with early onset IBD (younger than 5 years of age). We identified 16 patients with mutations in IL-10Ϫrelated genes: 5 patients had mutations in the IL10RA gene, 8 patients had mutations in the IL10RB gene, and 3 patients had mutations in the IL10 gene. Of those, 9 mutations had not been previously documented in IBD (1 stop codon mutation, 4 amino acid substitutions, 2 compound heterozygous mutations, 1 3=UTR mutation, and 1 deletion). Results of this mutational screening are summarized in Table 1 . Molecular details are displayed in Supplementary Figures 1A-C. In silico analysis using PolyPhen 17 predicted that all identified mutations with amino acid substitution are either probably or, in the case of patient 12, possibly damaging with respect to protein structure and function. In contrast, SIFT 18 analysis predicted tolerated protein function in IL-10RA Arg117Arg/Cys (patient 7) and IL-10RA Ile169Thr (patient 12) mutations. Bioinformatic studies on the 3=UTR mutation suggested that this sequence variation targets a putative SR-protein binding site.
Characterization of IL-10-and IL-10R-Deficient Patients
All patients with mutations in IL10 and IL10R genes presented with severe and progressive colitis in the first 3 months of life, fulfilling the criteria of infantile (very early onset) IBD. 16 
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Ileostomy (6 mo, g) 116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173   116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171 Figure 1A ). Histological analysis of colonic biopsies revealed unspecific acute colitis with multiple ulcerations and dense polymorphic infiltrations ( Figure 1B, C) , reminiscent of Crohn's disease. All patients had multimodal therapy, including exclusive enteral nutrition, antiinflammatory and/or immunomodulatory agents. Most patients underwent ileostomy, colostomy, and/or surgical intestinal resections. Despite complex multimodal therapy approaches, none of the patients had a sustained response. Detailed information on demographics, clinical phenotype, and treatment of individual IL-10/IL-10RϪde-ficient patients is provided in Table 1 .
We assessed the functional consequences of the mutations and assayed IL-10RϪdependent signaling in primary PBMCs from 10 patients. As shown in Figure 1D and Supplementary Figure 2A , deleterious mutations in IL10R genes abrogate IL-10Ϫmediated signaling resulting in deficient phosphorylation of signal transducer and activator of transcription 3 at the Tyr705 residue, an essential downstream target for the physiological antiinflammatory response of IL-10. As a consequence, IL10RϪdeficient primary cells are unresponsive to IL10Ϫdependent negative feedback regulation and secrete high amounts of TNF-␣ upon costimulation with LPS and IL-10 ( Figure 1E, F and Supplementary Figure 2B) . To analyze the functional impact of the IL-10 Gly153Asp mutation, we quantified the inhibition of TNF-␣ release in LPS-stimulated PBMCs from healthy donors upon stimulation with lentivirally overexpressed and secreted wildtype or mutant IL-10 ( Figure 2 ). Wild-type IL-10 induced suppression of TNF-␣ secretion comparable with recombinant human IL-10. In contrast, mutant IL-10 failed to exert anti-inflammatory effects.
Allogeneic HSCT
Based on our previous observation, 12 we performed allogeneic HSCT in 5 IL-10RϪdeficient patients unresponsive to immunosuppressive medication and surgical intervention. We used an immunosuppressive and myeloablative conditioning regimen consisting of alemtuzumab, fludarabine, treosulfan, and thiotepa ( Figure 3 ). Ciclosporin and mycophenolate mofetil were administered for GVHD prophylaxis. Age at transplantation 174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230 174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231   F2   F3 ranged from 10 months to 13 years and 9 months with a median of 8 years and 3 months. Further details of HSCT are summarized in Table 2 . Patients 1 and 5 received hematopoietic stem cells from a matched sibling donor, and patients 3, 4, and 6 underwent HSCT from a matched unrelated donor. Donors were HLA-compatible in 10 of 10 (patients 1, 3, and 5) and 9 of 10 (patient 4 and 6) alleles, as determined by highresolution molecular genotyping. Engraftment was achieved in all patients. However, patient 4 had graft rejection on day ϩ80, patient 5 developed mixed chimerism (day ϩ127, 93%), and patient 6 had a partial bone marrow failure. Donor-derived hematopoiesis post transplantation is displayed over time in Supplementary Figure  3 . After rejection of first graft from a 9 of 10 matched unrelated donor, patient 4 was subjected to retransplantation from another 9 of 10 matched unrelated donor resulting in a prompt and durable engraftment. To prevent disease recurrence after the development of mixed hematopoietic chimerism patient 5 received one donor lymphocyte infusion (1 ϫ 10 6 CD3 pos cells/kg body weight, day ϩ235) and the mixed chimerism remained stable (80%Ϫ82%, day ϩ248 to 416) without any overt clinical symptoms. Furthermore, no hospitalization was required since day 60 after HSCT. Antiviral ganciclovir or cidofovir therapy of human herpes virus 6 infection in patient 6 was associated with partial bone marrow suppression resulting in red blood cell and platelet deficiency. He was treated with a stem cell boost on day ϩ260 and recovered with his bone marrow leading to substantial clinical improvement of colitis.
All transplanted patients had viral infections or reactivations after HSCT (cytomegalovirus, adenovirus, rotavirus, human herpes virus 6) and some required antiviral treatment (cidofovir, ganciclovir, foscarnet, and aciclovir). Viral infections could be controlled in all patients without any long-term side effects. Patients 1, 4, and 6 developed acute GVHD responding to a short-term course of prednisone therapy. Patient 4 developed limited chronic skin GVHD without sclerosis or ulcers requiring treatment with steroids and tacrolimus.
To date, 4 patients achieved fast and sustained complete clinical remission at a median follow-up of 2 years after HSCT. Improvement of the clinical status was furthermore evidenced by ameliorated wound healing, accelerated growth, and reduced need for hospitalization. Importantly, colonoscopy ( Figure 4A ) and histopathological examination ( Figure 4B , C) of ileal and colonic biopsies revealed no evidence of active inflammation at 6 months after HSCT. Furthermore, functional studies on PBMCs isolated from transplanted IL-10RϪdeficient patients showed phosphorylation of signal transducer and activator of transcription 3 at Tyr705 upon stimulation with IL-10 comparable to healthy donors ( Figure 4D and Supplementary Figure 4A ). In addition, we could detect a 232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289   T2,AQ: 23-27   232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289 AQ: 8 AQ: 9
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substantial inhibition of TNF-␣ secretion in LPS/IL10Ϫcostimulated PBMCs from transplanted patients ( Figure 4E , F and Supplementary Figure 4B ). Taken together, the clinical data and functional studies suggest reconstitution of the IL-10RϪmediated signal transduction in IL-10RϪdeficient patients after allogeneic HSCT.
Discussion
We here provide a systematic study on the genetic etiology and a tailored therapy approach using allogeneic HSCT in children with IL-10R deficiency. Analyzing 66 early onset IBD patients, we identified 16 patients with loss-of-function mutations in IL10 or IL10R genes. A variety of mutations were discovered. Most patients were born to consanguineous parents and had homozygous biallelic mutations (point mutations or deletions). However, some patients also presented with compound heterozygous mutations.
Clinically, all patients with documented IL-10 or IL-10R deficiency presented in their first 3 months of life. However, our results do not exclude that patients with first presentation of symptoms later during infancy or early childhood may have defects in the IL-10Ϫmediated signaling. Our study suggests that patients with clinical history of severe refractory course of infantile IBD should be genotyped for mutations in IL10 and IL10R genes. We could not observe clear genotypeϪphenotype correlations in our cohort of IL-10-and IL-10RϪdeficient patients. For example, patient 1 and patient 2 (siblings sharing the same homozygous IL10RB mutation) had a remarkably distinct level of disease severity, suggesting that the phenotypic manifestation is dependent on other intrinsic or extrinsic factors that remain presently unknown.
Very-early-onset IBD represents a rare variant within the pediatric IBD population. In a prospective European registry including 2054 unselected newly diagnosed pediatric IBD patients (EuroKids 19 ), only 21 (1%) of 2022 informative patients manifested their bowel disease during infancy and, of those, only 5 (0.25%) within the first 3 months of life (de Bie CL & Escher JC, personal communication). Our cohort of 66 patients is prone to bias with respect to ethnic background and predominance of genetic factors in the pathogenesis of IBD. Nevertheless, mutations in IL-10Ϫrelated genes were only discovered in approximately one third of the patients with onset in the first year of life, indicating that infantile IBD is heterogeneous. Other monogenetic conditions associated with IBD must be taken into consideration. For example, mutations in XIAP, 20, 21 NCF1 (p47-phox), 22 and PIK3R1 23 can present with early onset IBD. We expect that additional monogenetic defects contributing to the pathogenesis of early-onset IBD will be discovered in the near future.
Current therapeutic strategies for pediatric IBD include the use of exclusive enteral nutrition, corticosteroids, mesalamine, sulfasalazine, immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), and antiϪTNF-␣ antibodies. 24 Knowledge of the underlying genetic etiol- ogy may open novel horizons for rational therapeutic strategies. Proof-of-principle for allogeneic HSCT has been provided in one patient with IL-10R deficiency. 12 In previous sporadic cases, allogeneic HSCT has been performed in adult IBD patients and favorable outcomes with respect to IBD were reported. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Thapar et al showed that bone marrow transplantation can be used for the treatment of intractable ulcerating enterocolitis of infants with undefined genetic defects. 37 Although our study suggests that allogeneic HSCT represents a causal therapeutic approach for IL-10RϪdeficient patients, a word of caution is warranted. Early-onset IBD might also be caused by dysfunction of nonhematopoietic cells, which would obviously not be corrected by allogeneic HSCT. Our experience and the data in the published literature should not be used as proof-of-concept for all early-onset IBD patients. A cautious attitude is supported by experimental studies in mice. Using a random mutagenesis screen, Brandl et al showed that MyD88/Trifdeficient mice are highly susceptible to dextran sulfate sodium-induced colitis. 38 Because MyD88 and Trif represent Toll-like receptor adaptor proteins, one could argue that MyD88-dependent signaling controls innate immune cells and that an allogeneic HSCT may correct this defect. However, mutant mice subjected to allogeneic HSCT had a marked aggravation of their clinical colitis phenotype and died much earlier than control animals. 38 This experimental mouse study exemplifies that the identification of a classical pathway controlling immune cells does not necessarily imply that an allogeneic HSCT approach is a promising therapeutic strategy. Disciplined and well-designed animal studies might be needed to determine whether defined monogenetic defects in humans with early onset IBD can be cured by allogeneic HSCT. HSCT should only be considered in the context of controlled clinical studies or on the basis of defined genetic mutations, such as in patients with IL-10R deficiency. Our study used a highly immunosuppressive conditioning regimen, including in vivo deletion of dendritic cells, in conjunction with intense gut decolonization. This strategy was chosen because, in contrast to patients with classical immunodeficiency disorders, IL-10R deficiency is characterized by hyperinflammation. Increased levels of inflammatory cytokines, such as TNF-␣, have been shown to correlate with the severity of acute GVHD after HSCT. 39 Similar to many other rare diseases, it is very difficult to provide empiric evidence for or against certain constituents of the conditioning regimen. Future studies might help to refine transplantation procedures. In summary, our study highlights that IL-10 and IL-10R deficiencies represent a defined subgroup of pediatric IBD patients, manifesting within the first 3 months of life. This condition is characterized by a severe and progressive course of colitis associated with perianal disease and variable extraintestinal manifestations, such as folliculitis and arthritis. We conclude that infantile IBD pa- 348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405   AQ: 11   C  O  L  O  R   348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405 tients with perianal disease should be genotyped for mutations in IL10 and IL10R genes. Furthermore, our results suggest that allogeneic HSCT can induce sustained remission of IL-10R deficiency without undue toxicities or severe GVHD . 464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521   AQ: 2   AQ: 3   464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521 AQ: 4 AQ: 5
